Outcome Measures | Placebo | Esaxerenone 0.625 mg/d | Esaxerenone 1.25 mg/d | Esaxerenone 2.5 mg/d | Esaxerenone 5 mg/d |
---|---|---|---|---|---|

UACR, mg/g Cr | n=73^{a}; 66^{b} | n=71^{a}; 68^{b} | n=72^{a}; 65^{b} | n=70^{a}; 66^{b} | n=72^{a}; 58^{b} |

Baseline, mean (SD) | 123 (58) | 117 (60) | 127 (69) | 125 (58) | 126 (62) |

Week 12, mean (SD) | 145 (191) | 113 (123) | 96 (110) | 81 (96) | 66 (63) |

Change from baseline, mean (SD) | 21 (181) | −4 (97) | −30 (104) | −39 (83) | −59 (65) |

Difference to baseline, geometric LS mean ratio [95% CI]^{c} | 0.9 [0.8 to 1.1] | 0.8 [0.7 to 0.9] | 0.6 [0.5 to 0.7] | 0.5 [0.4 to 0.6] | 0.4 [0.4 to 0.5] |

Difference to placebo, geometric LS mean ratio [95% CI]^{c} | — | 0.8 [0.7 to 1.0] | 0.7 [0.5 to 0.8] | 0.5 [0.4 to 0.7] | 0.5 [0.4 to 0.6] |

UACR remission rate, n (%) | 2 (3) | 5 (8) | 8 (12) | 14 (21) | 12 (21) |

Treatment difference, OR [95% CI]^{d} | — | 2.2 [0.4 to 12] | 4.4 [0.9 to 22] | 10 [2.1 to 49] | 10 [2.1 to 50] |

eGFR, ml/min per 1.73 m^{2} | n=73^{a}; 67^{b} | n=71^{a}; 68^{b} | n=72^{a}; 65^{b} | n=70^{a}; 66^{b} | n=72^{a}; 58^{b} |

Baseline, mean (SD) | 69 (18) | 65 (14) | 66 (18) | 68 (19) | 69 (18) |

Week 12, mean (SD) | 71 (21) | 66 (15) | 64 (23) | 66 (22) | 65 (19) |

Change from baseline, mean (SD) | 1 (6) | 0.3 (7) | −2 (8) | −2 (8) | −6 (8) |

Difference to baseline, LS mean [95% CI]^{e} | 1 [−0.5 to 3.0] | 0.4 [−1.3 to 2.2] | −2 [−3.5 to 0.1] | −2 [−3.5 to 0.1] | −7 [−8.6 to −4.8] |

Difference to placebo, LS mean [95% CI]^{e} | — | −0.8 [−3.3 to 1.7] | −3 [−5.5 to −0.5] | −3 [−5.5 to −0.5] | −8 [−10 to −5.3] |

Serum K^{+}, mEq/L | n=72^{a}; 66^{b} | n=71^{a}; 68^{b} | n=72^{a}; 65^{b} | n=70^{a}; 66^{b} | n=73^{a}; 59^{b} |

Baseline, mean (SD) | 4.3 (0.3) | 4.2 (0.3) | 4.3 (0.3) | 4.3 (0.3) | 4.2 (0.3) |

Week 12, mean (SD) | 4.2 (0.3) | 4.3 (0.4) | 4.4 (0.5) | 4.4 (0.4) | 4.6 (0.5) |

Change from baseline, mean (SD) | −0.1 (0.3) | 0.1 (0.3) | 0.1 (0.4) | 0.1 (0.4) | 0.4 (0.4) |

Difference to placebo [95% CI] | — | 0.2 [0.1 to 0.3] | 0.3 [0.1 to 0.4] | 0.2 [0.1 to 0.4] | 0.5 [0.4 to 0.6] |

UACR, urinary albumin-to-creatinine ratio; Cr, creatinine; LS, least squares; 95% CI, 95% confidence interval; —, not applicable; OR, odds ratio; K

^{+}, potassium.↵a Number of participants at baseline.

↵b Number of participants at week 12.

↵c On the basis of the analysis of covariance model, with treatment group as a factor and log-transformed baseline values of eGFR and sitting systolic BP as covariates. Estimates are back transformed and expressed as the ratio in the original scale.

↵d Adjusted for baseline UACR, eGFR, and sitting systolic BP.

↵e Adjusted for baseline eGFR.